Video

Q&A With Dipak Kotecha From the University of Birmingham: Comparing Use of Digoxin to Placebo or No Treatment in Patients

Author(s):

While digoxin has been a popular medication in the past, particularly for patients with atrial fibrillation, a recent study looked at whether the medication was indeed beneficial for treatment when compared to placebo or no pharmaceutical therapy at all. Digoxin may be a popular treatment for some patients, but often doctors cannot look at just one condition when treating and have to consider multiple factors and issues.

While digoxin has been a popular medication in the past, particularly for patients with atrial fibrillation, a recent study looked at whether the medication was indeed beneficial for treatment when compared to placebo or no pharmaceutical therapy at all.

Dipak Kotecha, PhD, from the University of Birmingham discussed the results of a recent trial looking at this subject during the European Soceity of Cardiology's Annual Confrence in London.

Digoxin may be a popular treatment for some patients, but often doctors cannot look at just one condition when treating and have to consider multiple factors and issues.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.